News

← News

Published on August 26, 2018

CONTACT INFORMATION

FOR INFORMATION

Peter Ciano (732) 823-4950 

pciano@trispharma.com

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

MONMOUTH JUNCTION, NJ, August 27, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based therapeutic products that address unmet patient needs today announced the joining of Jeffery Palmer as its new Vice President and Head of Quality & Compliance.

Jeffrey has worked for both large and mid-size pharmaceutical companies, and brings more than 20 years of pharmaceutical industry experience – including his most recent experience as site Head of Quality and his prior experience in Quality Management Systems, Compliance, Process improvement and Scale-up. A chemical engineer by training, Jeffrey began his pharmaceutical career at Alpharma (Actavis/Teva) as a Validation Engineer in Maryland, and then worked ten plus years in global quality systems at Schering-Plough/Merck, rising to Associate Director. For almost the past 4 years he has been at Lupin Pharmaceuticals, and most recently served as Quality head for its Somerset, NJ site where he managed all aspects of quality and compliance. Jeffrey holds a Chemical Engineering degree from Clarkson University and has an MBA from the University of Maryland.

“Jeffrey’s background, especially his experience in Quality Systems with his early focus on validation/process improvement makes him an ideal candidate as the Head of Quality & Compliance for Tris” said Ketan Mehta, President and Chief Executive Officer of Tris. “His successful track record in developing sustainable quality management systems, creating a company-wide quality culture and developing right-first-time teams that bring high-quality products to market is what Tris needs today.”

“I am honored to have the opportunity to lead the Tris Quality organization, and will do my part to ensure the highest standards of quality and continuous improvement at Tris. I am excited to work with my colleagues at Tris to serve the patients who depend on our products.” said Jeffrey Palmer.

Jack Goodson, FDA’s former National expert of Generic Drugs and Biologics, who has been Tris’ interim Head of Quality & Compliance for the past five months will continue to assist the Tris team as a consultant working with Jeffrey through the transition and focus on other compliance priorities.

About Tris Pharma

Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that address unmet patient needs. Using its proprietary technology platform, LiquiXR®, Tris has pioneered the delivery of sustained release in the liquid, chewable, orally disintegrating tablet, and other dosage forms that benefits a wide variety of patients and their unique needs. Tris’ Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris’ research, manufacturing and commercial facilities are located in Central New Jersey. For more information, please visit www.trispharma.com.